ESR1 and breast carcinoma: Analysis of breast cancer biopsy samples based on ER and GPER expression reveals that 43% of cases are ER+/GPER+, 19% are either ER+/GPER- or ER-/GPER+, and 19% are ER-/GPER- (Figure 3B) (410).